Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,208,256

« Back to Dashboard

Summary for Patent: 5,208,256

Title: Treatment of ocular hypertension with a synergistic combination for ocular administration
Abstract:A method for treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of (a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and (b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in an amount effective in treatment of ocular hypertension.
Inventor(s): Ueno; Ryuji (Hyogo, JP)
Assignee: R-Tech Ueno, Ltd. (Osaka, JP)
Application Number:07/703,660
Patent Claim Types:
see list of patent claims
Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,208,256

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2-132909May 22, 1990

International Patent Family for Patent: 5,208,256

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2042972► subscribe
Germany69105349► subscribe
Denmark0458588► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.